Canada’s Drug Agency (CDA-AMC)
In December 2023, it was announced that Canada’s Drug Agency would be built from CADTH. The work of the drug agency expands on CADTH’s existing mandate and functions — which spans drugs, medical devices, and clinical interventions — and includes new work streams such as:
- improving the appropriate prescribing and use of medications
- increasing pan-Canadian data collection and expanding access to drug and treatment data, including real-world evidence data
- reducing drug system duplication and lack of coordination
CADTH adopted the new name Canada’s Drug Agency (CDA-AMC) as of May 1, 2024. An official launch will occur later this year.
Ending Cervical Cancer in Canada is Possible
The Canadian Partnership Against Cancer is calling on partners in health care and communities across Canada to end cervical cancer in Canada by 2040. The Partnership is leading the development and implementation of a Canadian plan to achieve the World Health Organization (WHO)’s ... Read More »
The Canadian Partnership Against Cancer is calling on partners in health care and communities across Canada to end cervical cancer in Canada by 2040. The Partnership is leading the development and implementation of a Canadian plan to achieve the World Health Organization (WHO)’s ... Read More »
New CCRA Advisory Board Leadership
Effective January 1st, 2024, CCRA welcomes new CCRA Advisory Board chair, Dr. Dajan O’Donnell. Dajan is the Director of Scientific Affairs and Partnerships at the Cancer Research Society (CRS) and has work... Read More »
Effective January 1st, 2024, CCRA welcomes new CCRA Advisory Board chair, Dr. Dajan O’Donnell. Dajan is the Director of Scientific Affairs and Partnerships at the Cancer Research Society (CRS) and has work... Read More »